DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Huperzine A is an investigational drug.
There have been 11 clinical trials for Huperzine A. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and Seizures. The leading clinical trial sponsors are Biscayne Neurotherapeutics, Inc., Baylor College of Medicine, and Spaulding Rehabilitation Hospital.
Recent Clinical Trials for Huperzine A
|BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures||Biscayne Neurotherapeutics Australia Pty, Ltd.||Phase 1/Phase 2|
|BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures||Biscayne Neurotherapeutics, Inc.||Phase 1/Phase 2|
|Bioavailability, Safety, and Tolerability of BIS-001 ER||Melbourne Health||Phase 1|